Ambrx Biopharma Cayman, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to 2022.
  • Ambrx Biopharma Cayman, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $305K, a 136% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2022 was $1.94M, a 193600% increase from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2021 was $1K, unchanged from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2020 was $1K.
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $1.94M +$1.94M +193600% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-30
2021 $1K $0 0% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $1K +$3K Jan 1, 2020 Dec 31, 2020 20-F 2022-04-26
2019 -$2K Jan 1, 2019 Dec 31, 2019 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.